AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk KRAS G12D- or G12R-mutated pancreatic and colorectal cancer

O’Reilly EM, Wainberg ZA, Weekes CD, et al.
Presented at the American Society of Clinical Oncology Annual Meeting
June 2-6, 2023
Chicago, IL